Answers are grounded in this paper and cite their sources.
Human papillomavirus-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) is a growing subset of cancer cases distinct from HPV-negative by fewer genetic mutations and prevalent epigenetic dysregulation. We mapped H3K27ac-marked super-enhancers (SEs) via ChIP-seq in HPV+ patient-derived xenografts (PDXs) and normal oropharyngeal mucosa, identifying tumor-specific SE domains (T-SEDs) enriched for transcription factors (TFs) including TP63, FOSL1, and JUND. These SE-associated TFs regulate key oncogenic pathways and are downregulated by BRD4 inhibition with JQ1, highlighting sensitivity to epigenetic modulation. RNA-seq data revealed coordinated dysregulation of enhancer RNAs and mRNAs near T-SEDs, linked to upregulated pathways including epithelial-mesenchymal transition and E2F targets. JQ1 treatment significantly repressed these tumor-specific pathways, suggesting a therapeutic potential for targeting SE-driven transcription in HPV+ HNSCC. This study underscores the critical role of SEs in epigenetic and transcriptional dysregulation in HPV+ HNSCC, revealing therapeutic targets and providing a framework for future mechanistic studies in this area.
No takes yet. Share an insight, caveat, or question.
Zamunér et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: